Pasireotide Side Effects: Safety Signals and Warnings
Pasireotide safety concerns are compound-specific. The main listed side effects are Hyperglycemia (most significant), Diarrhea, and Nausea. The main warning signals are Hyperglycemia/diabetes - monitor blood glucose before and during treatment; may require anti-diabetic medication, Hepatotoxicity - monitor liver function tests, and QT prolongation - ECG monitoring recommended.
Direct Answer
Pasireotide (Signifor) is FDA-approved for Cushing's disease in patients who fail surgery or are not surgical candidates, with Phase 3 data demonstrating meaningful UFC normalization. Its multi-receptor somatostatin analog profile (SST1/2/3/5) differentiates it from octreotide and allows ACTH suppression that octreotide cannot achieve. A validated, targeted treatment for a rare pituitary disorder.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Growth Hormone
- Best for
- Cushing's disease (ACTH-secreting pituitary adenoma), multi-receptor somatostatin pharmacology, acromegaly (LAR formulation)
Reported Side Effects
- Hyperglycemia (most significant)
- Diarrhea
- Nausea
- Cholelithiasis
- Headache
- Abdominal pain
- Fatigue
Warnings
- Hyperglycemia/diabetes - monitor blood glucose before and during treatment; may require anti-diabetic medication
- Hepatotoxicity - monitor liver function tests
- QT prolongation - ECG monitoring recommended
- Gallstones - periodic ultrasound recommended
- Hypocortisolism possible in Cushing's disease - monitor cortisol levels
Known or Plausible Interactions
- Anti-diabetic medications (dose adjustment likely needed)
- QT-prolonging drugs (additive cardiac risk)
- Cyclosporine (decreased blood levels of cyclosporine)
- Bromocriptine (increased bioavailability of bromocriptine)
Regulatory Context
FDA-approved for Cushing's disease (2012, SC formulation) and acromegaly (2014, LAR formulation). Available by prescription only. Marketed as Signifor by Recordati Rare Diseases (formerly Novartis).
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | Cushing's Disease Control (Level A), Acromegaly Control (Level A), and Hyperglycemia (Level A) |
| Primary citation count | 3 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "Pasireotide Side Effects: Safety Signals and Warnings." Last reviewed 2026-04-04. https://examinepeptides.com/answers/pasireotide-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.